Amgen reported an 8% decline in Q1 revenues amid a challenging economic environment, primarily due to decreased demand for key products like Enbrel. While the company maintained its EPS guidance by effectively managing costs and highlighted strong international performance and pipeline advancements, the reduced revenue outlook may weigh on investor sentiment in the short term.

[0]